Aer Therapeutics, Inc.
Irina Gitlin started their work experience in 2000 as a Graduate Student Researcher at Harvard University. Irina then joined Arsenal Medical in 2006 as a Senior Scientist, where they managed pre-clinical studies for the development of a novel hemostatic dressing and identified and oversaw grant proposals. In 2012, they joined the University of California, San Francisco, initially as a Senior Program Manager, where they organized and managed Catalyst Awards and academic-industry alliances. Later, they became the Drug Development Lead, working on translating academic discoveries into valuable biomedical products. Currently, they hold the position of Co-Founder at Aer Therapeutics, Inc. and is also the VP of Research and Development.
Irina Gitlin earned a B.S. in Chemical Engineering from the University of Illinois Urbana-Champaign in 2000. Irina then went on to obtain a Ph.D. in Chemistry from Harvard University, completing their studies in 2006.
This person is not in the org chart
This person is not in any teams
Aer Therapeutics, Inc.
Aer Therapeutics is a clinical stage biopharmaceutical company developing a novel inhaled approach to treat lung disease with excess mucus and mucus plugs. We are focused on treating respiratory diseases with significant unmet need, such as COPD, cystic fibrosis and asthma. Our technology was developed and spun out of Dr. John Fahy’s airway biology lab at University of California San Francisco (UCSF) in collaboration with Dr. Stefan Oscarson’s glycochemistry lab at University College Dublin and Dr. Anne Marie Healy’s pharmaceutics lab at Trinity College Dublin. The efforts of this research consortium led to over $18M in NIH grant funding, resulting in the identification of our lead therapeutic candidate (AER-01), establishment of preliminary safety and efficacy profiles, and the production of clinical trial API.